Barclays PLC Raises Holdings in Ultralife Co. (NASDAQ:ULBI)

Barclays PLC lifted its stake in Ultralife Co. (NASDAQ:ULBI) by 21.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,395 shares of the technology company’s stock after purchasing an additional 2,355 shares during the quarter. Barclays PLC owned about 0.08% of Ultralife worth $121,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Rhumbline Advisers raised its holdings in shares of Ultralife by 1,728.3% in the second quarter. Rhumbline Advisers now owns 11,811 shares of the technology company’s stock worth $125,000 after buying an additional 11,165 shares during the last quarter. Juncture Wealth Strategies LLC purchased a new position in Ultralife in the 3rd quarter worth $165,000. Jane Street Group LLC acquired a new stake in Ultralife during the 3rd quarter worth about $166,000. XTX Topco Ltd grew its stake in Ultralife by 192.1% during the 2nd quarter. XTX Topco Ltd now owns 37,399 shares of the technology company’s stock valued at $397,000 after purchasing an additional 24,595 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Ultralife by 15.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 157,330 shares of the technology company’s stock valued at $1,422,000 after purchasing an additional 21,140 shares during the period. 30.68% of the stock is currently owned by institutional investors and hedge funds.

Ultralife Price Performance

Shares of ULBI opened at $8.22 on Friday. The business’s 50-day moving average is $7.60 and its two-hundred day moving average is $9.04. The company has a market capitalization of $136.67 million, a P/E ratio of 14.95 and a beta of 0.96. Ultralife Co. has a fifty-two week low of $6.63 and a fifty-two week high of $13.39. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.62 and a current ratio of 3.30.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Benchmark reaffirmed a “buy” rating and set a $14.00 target price on shares of Ultralife in a report on Friday, November 15th. StockNews.com cut shares of Ultralife from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 3rd.

Ultralife Company Profile

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.